Teriparatide biosimilar - Pfenex

Drug Profile

Teriparatide biosimilar - Pfenex

Alternative Names: PF-708

Latest Information Update: 19 Jan 2017

Price : $50

At a glance

  • Originator Pfenex
  • Class Osteoporosis therapies; Peptide hormones; Skin disorder therapies
  • Mechanism of Action Osteogenesis stimulants; Parathyroid hormone receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Clinical Phase Unknown Osteopetrosis

Most Recent Events

  • 16 Sep 2016 Pharmacokinetics and safety data from a clinical trial in Osteopetrosis reported at the 38th Annual Meeting of the American Society for Bone and Mineral Research (ASBMR-2016)
  • 09 May 2016 Pharmacokinetics data from a clinical trial in Osteopetrosis (In Volunteers) released by Pfenex
  • 21 Oct 2013 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top